The endorsement of an advisory committee positions Moderna to complete a dramatic turnaround for a shot the FDA declined to review earlier this year.

Ahead of a Thursday advisory panel meeting, agency scientists highlighted shortcomings in data accrued for a vaccine the FDA controversially refused to even review earlier this…

Moderna's novel vaccine was at the center of dustup with agency earlier this year

U.S. health advisers are debating a new kind of flu vaccine

Recommendation could pave the way for approval of the mRNA vaccine in adults 50 and up

In February, a Trump official refused to review the vaccine.